Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of topical N-chlorotaurine plus ammonium chloride for epidemic adenoviral keratoconjunctivitis
2007-002101-50Phase 2Completed
- Sponsor
- Acuity Pharmaceuticals, LLC
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in adenoviral keratoconjunctivitis (EKC) comparing N-chlorotaurine + ammonium chloride with Placebo (2 arms). Primary endpoint: Safety, tolerability and preliminary efficacy of topical N-chlorotaurine plus ammonium chloride. Started Jun 2007; status: completed.
02
Drugs
N-chlorotaurineammonium chloride
03
Conditions
adenoviral keratoconjunctivitis (EKC)
Beyond the preview
Go deeper on 2007-002101-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002101-50.